Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;128(1):e93.
doi: 10.1002/cpim.93.

Antibody-Based CAR T Cells Produced by Lentiviral Transduction

Sabrina Prommersberger  1 , Michael Hudecek  1 , Thomas Nerreter  1
Affiliations

Antibody-Based CAR T Cells Produced by Lentiviral Transduction

Sabrina Prommersberger et al. Curr Protoc Immunol. 2020 Mar.

Abstract

One promising approach to treat hematologic malignancies is the usage of patient-derived CAR T cells. There are continuous efforts to improve the function of these cells, to optimize their receptor, and to use them for the treatment of additional types of cancer and especially solid tumors. In this protocol, an easy and reliable approach for CAR T cell generation is described. T cells are first isolated from peripheral blood (here: leukoreduction system chambers) and afterwards activated for one day with anti-CD3/CD28 Dynabeads. The gene transfer is performed by lentiviral transduction and gene transfer rate can be verified by flowcytometric analysis. Six days after transduction, the stimulatory Dynabeads are removed. T cells are cultured in interleukin-2 conditioned medium for several days for expansion. There is an option to expand CAR T cells further by co-incubation with irradiated, antigen-expressing feeder cell lines. The CAR T cells are ready to use after 10 (without feeder cell expansion) to 24 days (with feeder cell expansion). © 2020 The Authors. Basic Protocol: Generation of CAR T cells by lentiviral transduction.

Keywords: CAR T cells; chimeric antigen receptor; lentiviral transduction.

PubMed Disclaimer

References

Literature Cited

    1. Birkholz, K., Hombach, A., Krug, C., Reuter, S., Kershaw, M., Kampgen, E., … Dorrie, J. (2009). Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Therapy, 16(5), 596-604. doi: 10.1038/gt.2008.189.
    1. Bridgeman, J. S., Hawkins, R. E., Bagley, S., Blaylock, M., Holland, M., & Gilham, D. E. (2010). The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. Journal of Immunology, 184(12), 6938-6949. doi: 10.4049/jimmunol.0901766.
    1. Charrot, S., & Hallam, S. (2019). CAR-T Cells: Future perspectives. HemaSphere, 3(2), e188. doi: 10.1097/hs9.0000000000000188.
    1. Gogishvili, T., Danhof, S., Prommersberger, S., Rydzek, J., Schreder, M., Brede, C., … Hudecek, M. (2017). SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes. Blood, 130(26), 2838-2847. doi: 10.1182/blood-2017-04-778423.
    1. Guedan, S., Posey, A. D., Jr., Shaw, C., Wing, A., Da, T., Patel, P. R., … June, C. H. (2018). Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight, 3(1), e96976. doi: 10.1172/jci.insight.96976.

Publication types

MeSH terms

LinkOut - more resources